Previous close | 52.24 |
Open | 52.00 |
Bid | 50.33 x 100 |
Ask | 50.42 x 100 |
Day's range | 49.93 - 52.26 |
52-week range | 25.35 - 55.78 |
Volume | |
Avg. volume | 760,316 |
Market cap | 4.034B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.76 |
Earnings date | 05 Nov 2024 - 11 Nov 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 70.38 |
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as induc
We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against the other mid-cap healthcare stocks. Global Healthcare Market: Growth Projections, Challenges, and Tech-Driven Innovations According to projections by ReportLinker, the market for healthcare […]
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September. Morg